Hospital-acquired Pneumonia Clinical Trial
Official title:
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
Verified date | July 2020 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups,
ventilator-associated pneumonia (VAP) and non-ventilator-associated HAP (nvHAP). Although
nvHAP occurs more frequently than VAP and results in similar mortality and costs, prevention
guidelines and prevention focus almost exclusively on VAP. Scientific evidence about nvHAP
prevention is scarce. Therefore, we designed a mixed-methods study to investigate the
effectiveness of a newly developed nvHAP prevention bundle and factors that influence its
implementation.
Methods: This single-centre project at the 950-bed University Hospital Zurich (UHZ) will
engage the wards of nine departments with substantial nvHAP rates. The nvHAP bundle consists
of five primary prevention measures: 1) oral care, 2) identification and treatment of
patients with dysphagia, 3) mobilization, 4) stopping unnecessary proton pump inhibitors,
and, 5) respiratory therapy. Implementation includes the engagement of department-level
implementation teams, who sustain the 'core' intervention components of education, training,
and environmental restructuring and adapt the implementation strategy to local needs. The
effects of the implementation will be analysed by a mixed-method approach. As primary
outcome, nvHAP incidence rates will be analysed by Poisson regression models to compare
incidence rates before, during, and after the implementation phases (on the hospital and
department level). In addition, the association between process indicators and nvHAP
incidence rates will be analysed using longitudinal Poisson regression models. A
longitudinal, qualitative study and formative evaluation based on interviews and focus groups
identifies supporting or hindering factors for implementation success in participating
departments dynamically over time. This accumulating implementation experience will be
constantly fed back to the implementation teams and thus, represents an active implementation
element.
Discussion: This comprehensive mixed-methods study is designed to accomplish both, measure
the effectiveness of a new prevention bundle against nvHAP and provide insights into how and
why it worked or failed. The results of this study may contribute substantially to patient
safety in the area of a rediscovered healthcare-associated infection - nvHAP.
Status | Terminated |
Enrollment | 45000 |
Est. completion date | February 28, 2020 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
The study population consists of all patients hospitalized in nine predefined medical and
surgical departments and their corresponding wards chosen based on the following criteria - nvHAP rate above the 50th percentile according to UHZ nvHAP data from the year 2017 - high absolute number of patients with nvHAP according to UHZ nvHAP data from the year 2017 - organizational structure, e.g. departments sharing same nursing or medical personnel - representing both medical and surgical specialties. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Zurich, Dept. of Infectious Diseases and Hospital Epidemiology | Zurich | ZH |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percentage of patients in whom the respective prevention measure was correctly applied (prevention measures are: oral care, mobilisation, dysphagia screening, stopping proton pump inhibitors, respiratory therapy) | Aderence to the five prevention measures: oral care, Identification and treatment of patients with dysphagia, mobilization, Stop proton pump inhibitors if not indicated, respiratory physiotherapy | at four timepoints (baseline, 2-3 months 4-6 months and 10-12 months after start implentation, 10 | |
Other | Adherence score per department and timepoint | The 'nvHAP adherence score' is calculated by summing up the five proportions of executed prevention measures (i.e. nvHAP adherence indicator = 1) and dividing it by factor five. In the above example it would be (32/45 + 20/50 + 48/50 + 42/50 + 24/32)/5 = 0.732. | at four timepoints (baseline, 2-3 months 4-6 months and 10-12 months after start implentation, 10 | |
Other | Implementation success evaluated by semi-structured interview and focus group interview | We will use a qualitative definition of implementation success composed of the following four implementation outcomes: acceptability, appropriateness, protocol fidelity, and sustainability | at three timepoints ( 2-3 months 4-6 months and 10-12 months after start implentation, 10 | |
Primary | nvHAP Incidence rate | non Ventilator-associated Hospital acquired Pneumonia according to ECDC definitions | up to 3 months post-discharge | |
Secondary | Percentage of patients who passed away during hospitalization (in-hospital mortality) | death during hospitalisation | up to 3 months post-discharge | |
Secondary | length of stay | Duration of hospitalisation | up to 3 months post-discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01266863 -
E Test Strips Applied to Bronchoalveolar Lavage for Suspicion of Hospital-acquired Pneumonia to Accelerate Antibiogram Analysis.
|
N/A | |
Not yet recruiting |
NCT06168734 -
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
|
Phase 3 | |
Not yet recruiting |
NCT01940731 -
Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults
|
Phase 2 | |
Not yet recruiting |
NCT06028217 -
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
|
||
Completed |
NCT01561469 -
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
|
N/A | |
Terminated |
NCT00543608 -
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
|
Phase 2 | |
Enrolling by invitation |
NCT04055922 -
Comparison of Solid Organ Transplant
|
||
Completed |
NCT04403971 -
0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia
|
N/A | |
Completed |
NCT04774094 -
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
|
Phase 4 | |
Completed |
NCT05060718 -
HOspital NEtwork STudy - Preparation for a Randomized Evaluation of Anti-Pneumonia Strategies
|
||
Active, not recruiting |
NCT05785442 -
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
|
Phase 2 | |
Completed |
NCT04700202 -
Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit
|
||
Not yet recruiting |
NCT05418517 -
Hospital Acquired Pneumonia in Temporary Tracheostomy
|
||
Recruiting |
NCT04381247 -
Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway
|
||
Recruiting |
NCT05483309 -
Feasibility Study of Contemporary Diagnostics for Patients With Suspected Hospital-Acquired Pneumonia.
|
N/A | |
Completed |
NCT04937075 -
Impact of Antimicrobial Stewardship on Outcomes of Patients With Hospital-acquired Pneumonia Due to Gram-negative Bacilli - A Before-after Study
|
||
Completed |
NCT03496220 -
Effect of Angulus on Patient-elevation Compliance
|
N/A | |
Not yet recruiting |
NCT05914584 -
"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
|
Phase 2/Phase 3 | |
Completed |
NCT05663905 -
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
|
Phase 4 | |
Completed |
NCT05624684 -
Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.
|